|

TGI-5 Clinical Trials

1 actively recruiting trial

Also known as: Nivolumab

Pipeline

Phase 1: 1

Top Sponsors

  • Hefei TG ImmunoPharma Co., Ltd.1

Indications

  • Liver Disease1
  • Melanoma (Skin Cancer)1
  • CRC (Colorectal Cancer)1
  • NSCLC (Non-small Cell Lung Cancer)1
  • HCC - Hepatocellular Carcinoma1

Other1 trial

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.